Greenwich Pharmaceuticals Inc. announced Monday that it hasraised nearly $6 million from the sale of its equity securities.
"These additional funds will be used primarily to accelerate ourstrategic sales and marketing efforts for Therafectin, which isbeing developed as a chronic treatment for rheumatoidarthritis," said Edwin Thompson, chief executive officer of theFort Washington, Pa., company.
Greenwich Pharmaceuticals (NASDAQ:GRPI) submitted a newdrug application (NDA) on Therafectin to the FDA on March 12,and a product license application (PLA) in the United Kingdomon April 14.
(c) 1997 American Health Consultants. All rights reserved.